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A B S T R A C T
Background
The use of supplemental oxygen in the care of extremely preterm infants has been common practice since the 1940s. Despite this,
there is little agreement regarding which oxygen saturation (SpO ) ranges to target to maximise short- or long-term growth and
development, while minimising harms. There are two opposing concerns. Lower oxygen levels (targeting SpO at 90% or less) may
impair neurodevelopment or result in death. Higher oxygen levels (targeting SpO greater than 90%) may increase severe retinopathy
of prematurity or chronic lung disease.
The use of pulse oximetry to non-invasively assess neonatal SpO levels has been widespread since the 1990s. Until recently there
were no randomised controlled trials (RCTs) that had assessed whether it is better to target higher or lower oxygen saturation levels in
extremely preterm infants, from birth or soon thereafter. As a result, there is significant international practice variation and uncertainty
remains as to the most appropriate range to target oxygen saturation levels in preterm and low birth weight infants.
Objectives
1. What are the effects of targeting lower versus higher oxygen saturation ranges on death or major neonatal and infant morbidities, or
both, in extremely preterm infants?
2. Do these effects differ in different types of infants, including those born at a very early gestational age, or in those who are outborn,
without antenatal corticosteroid coverage, of male sex, small for gestational age or of multiple birth, or by mode of delivery?
Search methods
We used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL
2016, Issue 4), MEDLINE via PubMed (1966 to 11 April 2016), Embase (1980 to 11 April 2016) and CINAHL (1982 to 11 April
2016). We also searched clinical trials databases, conference proceedings and the reference lists of retrieved articles for randomised
controlled trials.
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Selection criteria
Randomised controlled trials that enrolled babies born at less than 28 weeks’ gestation, at birth or soon thereafter, and targeted SpO
ranges of either 90% or below or above 90% via pulse oximetry, with the intention of maintaining such targets for at least the first two
weeks of life.
Data collection and analysis
We used the standard methods of Cochrane Neonatal to extract data from the published reports of the included studies. We sought
some additional aggregate data from the original investigators in order to align the definitions of two key outcomes. We conducted the
meta-analyses with Review Manager 5 software, using the Mantel-Haenszel method for estimates of typical risk ratio (RR) and risk
difference (RD) and a fixed-effect model. We assessed the included studies using the Cochrane ’Risk of bias’ and GRADE criteria in
order to establish the quality of the evidence. We investigated heterogeneity of effects via pre-specified subgroup and sensitivity analyses.
Main results
Five trials, which together enrolled 4965 infants, were eligible for inclusion. The investigators of these five trials had prospectively
planned to combine their data as part of the NeOProM (Neonatal Oxygen Prospective Meta-analysis) Collaboration. We graded the
quality of evidence as high for the key outcomes of death, major disability, the composite of death or major disability, and necrotising
enterocolitis; and as moderate for blindness and retinopathy of prematurity requiring treatment.
When an aligned definition of major disability was used, there was no significant difference in the composite primary outcome of death
or major disability in extremely preterm infants when targeting a lower (SpO 85% to 89%) versus a higher (SpO 91% to 95%)
oxygen saturation range (typical RR 1.04, 95% confidence interval (CI) 0.98 to 1.10; typical RD 0.02, 95% CI -0.01 to 0.05; 5 trials,
4754 infants) (high-quality evidence). Compared with a higher target range, a lower target range significantly increased the incidence
of death at 18 to 24 months corrected age (typical RR 1.16, 95% CI 1.03 to 1.31; typical RD 0.03, 95% CI 0.01 to 0.05; 5 trials,
4873 infants) (high-quality evidence) and necrotising enterocolitis (typical RR 1.24, 95% 1.05 to 1.47; typical RD 0.02, 95% CI
0.01 to 0.04; 5 trials, 4929 infants; I² = 0%) (high-quality evidence). Targeting the lower range significantly decreased the incidence
of retinopathy of prematurity requiring treatment (typical RR 0.72, 95% CI 0.61 to 0.85; typical RD -0.04, 95% CI -0.06 to -0.02;
5 trials, 4089 infants; I² = 69%) (moderate-quality evidence). There were no significant differences between the two treatment groups
for major disability including blindness, severe hearing loss, cerebral palsy, or other important neonatal morbidities.
A subgroup analysis of major outcomes by type of oximeter calibration software (original versus revised) found a significant difference
in the treatment effect between the two software types for death (interaction P = 0.03), with a significantly larger treatment effect
seen for those infants using the revised algorithm (typical RR 1.38, 95% CI 1.13 to 1.68; typical RD 0.06, 95% CI 0.01 to 0.10; 3
trials, 1716 infants). There were no other important differences in treatment effect shown by the subgroup analyses using the currently
available data.
Authors’ conclusions
In extremely preterm infants, targeting lower (85% to 89%) SpO compared to higher (91% to 95%) SpO had no significant effect
on the composite outcome of death or major disability or on major disability alone, including blindness, but increased the average risk
of mortality by 28 per 1000 infants treated. The trade-offs between the benefits and harms of the different oxygen saturation target
ranges may need to be assessed within local settings (e.g. alarm limit settings, staffing, baseline outcome risks) when deciding on oxygen
saturation targeting policies.
P L A I N L A N G U A G E S U M M A R Y
Targeting lower or higher oxygen levels in preterm infants
Review question: Is it better to target a lower or higher level of oxygen for babies born very early?
Background: Giving additional (’supplemental’) oxygen to babies born very early (’extremely preterm infants’) who have breathing
difficulties has been common practice since the 1940s. Despite this, there is little agreement as to what levels of oxygen will maximise
short- or long-term survival and development. Technology (’pulse oximetry’) that can easily measure the level of oxygen in a baby’s
blood (oxygen saturation) has been in widespread use since the 1990s. Despite this, until recently there were no randomised trials
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that had tested whether it is better to target lower or higher oxygen saturation levels in extremely preterm infants, from birth or soon
thereafter. As a result there is a great deal of variation in the target ranges aimed for in different newborn care units around the world.
Study characteristics: The studies we included were randomised trials that enrolled babies born at less than 28 weeks’ gestation, at
birth or soon thereafter, and targeted oxygen saturation (SpO ) ranges of either 85% to 89% or 91% to 95%, for at least the first two
weeks of life.
Key results: We included five trials, which together enrolled 4965 infants, in this review. There were benefits and harms associated
with both the target ranges tested. Neither the lower nor the higher target range had a significant effect on the rate of death or major
disability (the main outcome), on major disability alone or on blindness. However, infants in whom the lower oxygen range was targeted
had, on average, a 2.8% increased risk of death, compared to the infants in whom the higher oxygen range was targeted. They also
had a 2.2% increase in the rate of a serious bowel condition known as necrotising enterocolitis. Conversely, the infants in whom the
lower oxygen range was targeted had a 4.2% decrease in the rate of a serious eye problem, retinopathy of prematurity, requiring surgery
or other treatments. The trade-offs between these benefits and harms may need to be assessed within local settings when deciding on
oxygen saturation targeting policies.
Quality of evidence: We rated the quality of the evidence as high for the key outcomes of death, major disability, the composite of
death or major disability, and necrotising enterocolitis. We rated the quality of evidence as moderate for the two eye-related outcomes
(blindness, retinopathy of prematurity requiring treatment), giving us confidence that the overall results are reliable.
3Effects of targeting lower versus higher arterial oxygen saturations on death or disability in preterm infants (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Lower compared to higher targeted oxygen saturations (no subgroups) in preterm infants
Patient or population: extremely preterm infants
Setting: neonatal intensive care units
Intervention: lower oxygen saturat ion targets
Comparison: higher oxygen saturat ions targets (no subgroups)
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with higher tar-
geted oxygen satura-
tions (no subgroups)
Risk with lower tar-
geted oxygen satura-
tions
Death or major disabil-
ity by 18 to 24 months
corrected age (aligned
def init ion)
Study populat ion RR 1.04
(0.98 to 1.10)
4754
(5 RCTs)
⊕⊕⊕⊕
HIGH
-
493 per 1000 513 per 1000
(483 to 542)
Death to 18 to 24
months corrected age
Study populat ion RR 1.16
(1.03 to 1.31)
4873
(5 RCTs)
⊕⊕⊕⊕
HIGH
-
171 per 1000 199 per 1000
(176 to 224)
Major disability by 18
to 24 months corrected
age (aligned def init ion)
Study populat ion RR 1.01
(0.93 to 1.09)
3867
(5 RCTs)
⊕⊕⊕⊕
HIGH
-
383 per 1000 387 per 1000
(356 to 417)
Retinopathy of prema-
turity requiring treat-
ment
Study populat ion RR 0.72
(0.61 to 0.85)
4089
(5 RCTs)
⊕⊕⊕©
MODERATE 1
-
148 per 1000 106 per 1000
(90 to 125)
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Necrot ising enterocoli-
t is
Study populat ion RR 1.24
(1.05 to 1.47)
4929
(5 RCTs)
⊕⊕⊕⊕
HIGH
-
90 per 1000 112 per 1000
(95 to 133)
Blindness Study populat ion RR 1.13
(0.65 to 1.97)
3875
(5 RCTs)
⊕⊕⊕©
MODERATE 2
-
12 per 1000 13 per 1000
(8 to 23)
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval;RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded to moderate for inconsistency due to moderate heterogeneity (I² = 72%).
2Downgraded to moderate for imprecision due to low event rates.
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B A C K G R O U N D
Description of the condition
The administration of supplemental oxygen has a long history in
neonatal care (Wilson 1942; Tin 2007). Oxygen was used liberally
for the first time in neonates in the 1930s when an oxygen unit
was described for preterm infants (Raju 1999). The use of oxy-
gen in preterm and low birth weight infants suffering respiratory
insufficiency has resulted in significant healthcare benefits, such
as reduced mortality and spastic diplegia (Avery 1960; McDonald
1963), but has also been associated with significant deleterious
effects such as retinopathy of prematurity and lung toxicity (Duc
1992).
Improvements in technology in the past few decades have led to
the increased survival of preterm and low birth weight infants.
One of these advances is the ability to measure oxygen levels more
accurately. Despite the exceedingly common use of supplemental
oxygen in this population of infants, there is little consensus as to
the optimal levels of oxygen for maximising short- or long-term
growth and development, while minimising harmful effects (Poets
1998; McIntosh 2001; Silverman 2004).
Adverse consequences of liberal and restricted use of
oxygen
The adverse consequences of liberal oxygen use were recognised
in the early 1940s. Terry 1942 described a type of blindness in
preterm infants characterised by a thick fibrotic membrane in the
retrolental space. In 1951, the role of supplemental oxygen in the
aetiology of ’retrolental fibroplasia’ was first suggested (Campbell
1951). By 1954, retrolental fibroplasia had blinded about 10,000
infants (Silverman 1980; Silverman 2004). From 1954 to 1956,
three randomised trials (Lanman 1954; Patz 1954; Kinsey 1956),
enrolling 341 infants, proved that breathing unrestricted concen-
trations of inspired oxygen was a major cause of retrolental fi-
broplasia (Askie 2009). Throughout this period, oxygen admin-
istration was guided by the clinical observations of skin colour,
as well as the rate, regularity and work of breathing. It was not
until the 1960s and 1970s that sampling of blood gases, transcuta-
neous oxygen monitoring and later pulse oximetry became avail-
able for more precise monitoring of oxygen levels (Walsh 2009).
An early prospective cohort study, reported in 1977, was unable
to establish a causal relationship between arterial oxygen tension
and (what is now known as) retinopathy of prematurity (ROP),
but did reveal that the most relevant factors for developing ROP
were birth weight less than 1200 grams and length of exposure to
supplemental oxygen (Kinsey 1977).
As a consequence of the retrolental fibroplasia blindness epidemic
in the 1960s, the use of oxygen was drastically limited, usually
to less than 40% inspired oxygen, even for preterm infants with
respiratory distress, allowing them to become severely hypoxaemic
and leading to a substantial increase in the incidence of cerebral
palsy (Usher 1961). In the next 20 years over 150,000 premature
babies died of hypoxic respiratory failure (Avery 1960; McDonald
1964; Cross 1973; Bolton 1974). It is estimated that for every
infant whose sight was saved, 16 died (Avery 1960; Silverman
2004), and many others developed spastic diplegia (McDonald
1964).
Description of the intervention
Multiple attempts have beenmade to establish the optimal oxygen
levels in preterm infants, using a variety of technologies, in order to
circumvent the adverse consequences of either restricted or liberal
use of supplemental oxygen.
However, what constitutes an ’appropriate’ level of oxygen for in-
fants born preterm, who would otherwise be in-utero, remains
unknown. The fetus is relatively hypoxic with haemoglobin (Hb)
oxygen saturations of 65%, 55%, and45% in the aorta, pulmonary
artery and pulmonary vein, respectively. However, it should be
noted that fetal blood contains almost only fetal haemoglobin
(HbF), which has an extraordinary affinity for oxygen and is there-
fore capable of capturing sufficient oxygen from the intervillous
space to support fetal growth and metabolism (Gao 2010; Vento
2013).
In the 1980s and early 1990s the use of transcutaneous oxygen
monitoring became available. A study of transcutaneous oxygen
monitoring (TcO ) in preterm infants confirmed that ROP oc-
curred more often when longer periods of time were spent with
a TcO above 80 mm Hg, but did not determine if another
limit was safer (Flynn 1992). A partial pressure of arterial oxygen
(PaO ) range of 50 to 80 mm Hg became widely accepted as
an appropriate level to target (AAP 1988; McIntosh 2001; AAP
2002), but this was based on professional consensus rather than
on evidence.
In the 1990s the use of pulse oximetry became a standard of care
and continuous monitoring has allowedmore frequent titration of
the oxygen concentration administered. Pulse oximetry (SpO )
refers to the estimation of the oxygen saturation of arterial blood
using a device that measures the pulsatile changes in light trans-
mission across a tissue bed. Pulse oximeters work on the principle
that oxygenated and deoxygenated haemoglobin absorbs light of
different wavelengths (red and infrared). The oximeter emits light
of these two wavelengths and measures absorption in the pulsatile
element of the blood flow, thus producing a measure of the oxygen
saturation of arterial blood separate from the non-pulsatile venous
blood (Williams 1998). Pulse oximeters lack the heat-related side
effects of transcutaneous oxygen monitors.
Despite the ease of use of pulse oximeters, translation of SpO
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values into PaO can be difficult to establish. The relationship
between SpO and PaO is dependent on various physiologic
circumstances such as affinity of Hb for oxygen, which is signifi-
cantly greater in fetal Hb. Thus, the higher the fetal Hb concen-
tration the higher the SpO would be for any given PaO value.
Castillo 2008 reported that in preterm infants, for oxygen satu-
ration values between 85% and 93% the mean measured PaO
was 56 ± 14.7 mm Hg. Within this SpO range, 87% of the
samples had PaO values of 40 to 80 mm Hg, 8.6% had values
of less than 40 mmHg, and 4.6% had values greater than 80 mm
Hg. When the SpO was greater than 93% the mean PaO was
107.3 ± 59.3 mmHg with 60% of values greater than 80 mmHg.
The Supplemental Therapeutic Oxygen for Prethreshold
Retinopathy of Prematurity trial used pulse oximetry to target a
lower (89% to 94%) or higher (96% to 99%) oxygen saturation
range in 649 preterm infants with prethreshold ROP who were 35
weeks postmenstrual age at randomisation (STOP ROP 2000).
The higher range caused more adverse respiratory events includ-
ing pneumonia, chronic lung disease requiring oxygen, and di-
uretic therapy. There was no statistically significant difference in
the rate of progression to threshold ROP. The results of this trial
are included in a separate Cochrane Review entitled: Supplemen-
tal oxygen for the treatment of pre-threshold retinopathy of prematu-
rity (Lloyd 2003). In the Benefits of Oxygen Saturation Target-
ing (BOOST) trial (Askie 2003), 358 infants born at less than 30
weeks’ gestationwere randomly assigned, from threeweeks ormore
after birth (at 32 weeks’ postmenstrual age) until they breathed
air, to target an SpO range of either 91% to 94% or 95% to
98% using masked offset oximeters. This trial found no evidence
that higher SpO targeting improved growth or development,
but it did increase days of oxygen therapy and use of healthcare re-
sources. The authors concluded that further large randomised tri-
als were needed to determine how targeting different SpO levels
from the day of birth affects ROP, chronic lung disease, growth,
disability, and mortality (Askie 2003; Silverman 2004).
In transposing oxygen tensions of 50 to 80mmHg into equivalent
arterial oxygen saturation, most clinicians have targeted functional
SpO at 90% to 95%with aminimum acceptable SpO of 85%
(Anderson 2004).Hence the dichotomising of SpO into ’higher’
or ’lower’ target ranges above or below a cut point of 90% appears
reasonable. In the early 2000s, there were several observational
studies that found lower SpO was associated with less severe
ROP; improved short-term respiration, growth and development
outcomes; and either no apparent effect or a decrease in mortality
(Tin 2001; Chow 2003; Anderson 2004).
It should be recognised that an intention to target a certain SpO
range does not guarantee that an infant’s actual SpO will always
be maintained within that range. Most studies report that preterm
infants receiving supplemental oxygen in a specified target range
only remain in that range for about 30% to 50% of the time
(Hagadorn 2006; Lim 2014).
To address the continuing uncertainty regarding the appro-
priate levels of oxygen saturation targeting for preterm in-
fants with sufficient confidence, the Neonatal Oxygen Prospec-
tive Meta-analysis (NeOProM) Collaboration was formed
in 2003. NeOProM is a prospective meta-analysis collab-
oration (Askie 2011), which includes five randomised tri-
als (ACTRN12605000055606; ACTRN12605000253606;
NCT00233324; ISRCTN00842661; ISRCTN62491227). The
investigators of these five trials prospectively agreed to conduct
their trials using very similar protocols, and made a commitment
to combine their individual participant data once their own trial’s
results were published. Representatives from each of these five tri-
als and the NeOProM Collaboration are authors on this review.
Summary
There are two opposing concerns. Less inspired oxygen (targeting
SpO at 90% or less) may increase the risk of death from chronic
hypoxaemia or impaired neurodevelopment (Newburger 1984;
Skinner 1999; Subhedar 2000). More inspired oxygen (targeting
SpO greater than 90%) may increase severe ROP (Hellstrom
2013), or chronic lungdisease (Warner 1998;Tin 2001; Sun 2002;
Chow 2003; Anderson 2004). However, uncertainty remains as
to the most appropriate range to target for blood oxygen levels in
preterm and low birth weight infants.
Two other related Cochrane Reviews have summarised the find-
ings on gradual versus abrupt (Askie 2001a), and early versus late
discontinuation of oxygen therapy (Askie 2001b), in preterm or
low birth weight infants. Meta-analyses of the available aggregate
data from the five NeOProM trials were published by Saugstad
2014, Manja 2015, Stenson 2016, and Manja 2017 and a sub-set
of data relating to retinopathy of prematurity outcomes by Fang
2016.
How the intervention might work
Oxygen is the most common therapy used in the care of very
preterm infants. It has been associated with significant improve-
ments in neonatal survival and reduced disability (Avery 1960).
However, preterm infants are highly sensitive to the harmful bio-
chemical and physiological effects of supplemental oxygen. Toxic
oxygen radicals are increased in hyperoxia (Maltepe 2009), and in
re-oxygenation after hypoxaemia. Preterm infants are vulnerable to
oxidative stress because they lack antioxidant protection (Saugstad
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2001) from plasma radical scavengers, such as beta-carotene, and
antioxidant enzymes, such as glutathione peroxidase, and their red
blood cells and cells of other organs (e.g. lungs) lack superoxide
dismutase.
Targeting a higher oxygen level contributes to bronchopulmonary
dysplasia (Warner 1998; Jobe 2001; Vento 2009; Kapadia 2013).
Relatively recent epidemiological/observational studies (Tin 2001;
Sun 2002; Chow 2003; Anderson 2004), and small randomised
trials from the 1950s (Askie 2009), have suggested that targeting
lower oxygen saturation levels may reduce severe ROP. The effects
on death or neurodisability of targeting either lower or higher
oxygen saturation levels frombirth have not yet been fully assessed.
Why it is important to do this review
Extreme prematurity of less than 28 weeks’ gestation affects ap-
proximately 1%of births (Centre for Epi 2012). Although approx-
imately 80% of these infants are discharged home alive (Chow
2013), they often sustain severe morbidity (Doyle 2010), includ-
ing chronic lung disease, poor growth, respiratory illness, hospital
re-admissions, visual deficits, cerebral palsy, neurodevelopmental
disability and cognitive, educational, and behavioural impairment
(Anderson 2003). It is essential to determine whether the range
of targeted SpO levels affects the occurrence of such outcomes
and, if possible, to determine the optimal range formanagement of
the very vulnerable preterm infant. Very preterm infants account
for a high proportion of the costs and disability from neonatal
intensive care (Sutton 1999). Reducing these morbidities would
enhance quality of life for these infants and benefit their families
and communities (Saigal 2000).
O B J E C T I V E S
1. What are the effects of targeting lower versus higher oxygen
saturation ranges on death or major neonatal and infant
morbidities, or both, in extremely preterm infants?
2. Do these effects differ in different types of infants,
including those born at a very early gestational age, or in those
who are outborn, without antenatal corticosteroid coverage, of
male sex, small for gestational age or of multiple birth, or by
mode of delivery?
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials. We excluded quasi-
randomised trials and cluster-randomised trials.
Types of participants
Participants in the eligible trials were infants either inborn or out-
born before 28 weeks’ gestation.
Types of interventions
The intervention was the used of pulse oximetry to target either
a lower (SpO less than or equal to 90%) or higher (SpO
greater than 90%) oxygen saturation range by 24 hours after birth,
maintaining these ranges for at least the first two weeks of life.
There was no minimum required level of compliance for keeping
within the target ranges. Oxygen targeting could be achieved by
either manual or machine-assisted methods.
Types of outcome measures
We assessed longer-term outcomes in infancy from 18 months
corrected for gestational age onwards, depending on the measure-
ment time point used by individual trials.
Primary outcomes
• Composite outcome of death or major disability by 18 to
24 months corrected for gestational age (aligned definition,
trialist defined)
Secondary outcomes
• Death (to discharge, to 18 to 24 months corrected for
gestational age follow-up)
• Major disability by 18 to 24 months corrected for
gestational age (aligned definition, trialist defined)
• Retinopathy of prematurity (ROP) treatment by laser
photocoagulation, cryotherapy or bevacizumab treatment
• Measures of respiratory support, defined as (a)
supplemental oxygen requirement at 36 weeks postmenstrual age
(trialist defined), (b) days of endotracheal intubation, (c) days of
continuous positive airway pressure (CPAP), (d) days of
supplemental oxygen, (e) days on home oxygen
• Patent ductus arteriosus requiring medical treatment
(defined as using cyclo-oxygenase inhibitors) or surgical
treatment
• Necrotising enterocolitis
• Weight at 36 weeks postmenstrual age, discharge home and
18 or 24 months corrected for gestational age
• Proportion of infants re-admitted to hospital up to 18 to 24
months corrected for gestational age
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• Cerebral palsy with Gross Motor Functioning Classification
System (GMFCS) level 2 or higher, or Manual Ability
Classification System (MACS) level 2 or higher at 18 to 24
months corrected for gestational age
• Blindness
• Severe hearing loss
• Quantitative Bayley III scores (Composite Cognitive Score
(CCS) and Composite Language Score (CLS) scores)
Search methods for identification of studies
We used the standard search methods of Cochrane Neonatal.
Electronic searches
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL 2016, Issue 4), MEDLINE via PubMed (1966 to
11 April 2016), Embase (1980 to 11 April 2016) and CINAHL
(1982 to 11 April 2016). We used the following search strategy:
Search strategy for search dates 1940 to January 1975
Search terms: (oxygen OR oxygen saturation OR hypoxia OR
retinopathy of prematurity OR retrolental fibroplasia OR hy-
peroxia) AND ( ( Clinical Trial[ptyp] OR Controlled Clini-
cal Trial[ptyp] OR Randomized Controlled Trial[ptyp] ) AND
( “1940/01/01”[PDat] : “1975/01/01”[PDat] ) AND Hu-
mans[Mesh] AND ( infant, newborn[MeSH] OR infant[MeSH]
))
Search strategy for search dates February 1975 to 11 April
2016
Search terms: (oxygen OR oxygen saturation OR hypoxia OR
retinopathy of prematurity OR retrolental fibroplasia OR hyper-
oxia)
We also used the following database-specific terms:
CENTRAL: (infant or newborn or neonate or neonatal or pre-
mature or very low birth weight or low birth weight or VLBW or
LBW)
PubMed: ((infant, newborn[MeSH] OR newborn OR neonate
OR neonatal OR premature OR low birth weight OR VLBW
OR LBW or infan* or neonat*) AND (randomized controlled
trial [pt] OR controlled clinical trial [pt] OR randomized [tiab]
OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR
trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans
[mh]))
Embase: (infant, newborn or newborn or neonate or neonatal or
premature or very low birth weight or low birth weight or VLBW
or LBW or Newborn or infan* or neonat*) AND (human not
animal) AND (randomized controlled trial or controlled clinical
trial or randomized or placeboor clinical trials as topic or randomly
or trial or clinical trial)
CINAHL: (infant, newbornORnewbornORneonateORneona-
tal OR premature OR low birth weight OR VLBW OR LBW
or Newborn or infan* or neonat*) AND (randomized controlled
trial OR controlled clinical trial OR randomized OR placebo OR
clinical trials as topic OR randomly OR trial OR PT clinical trial)
We searched for any ongoing or recently completed and un-
published trials, using the World Health Organization portal (
www.who.int/ictrp).
We did not apply any language, date or publication status restric-
tions.
Searching other resources
We searched previous reviews and cross-references, abstracts, and
conference and symposia proceedings. We contacted expert in-
formants and carried out journal handsearching. We searched the
abstracts of the relevant perinatal meetings (including Society for
Pediatric Research, Neonatal Register) for the years 1985 to the
present, using the following keywords: ’oxygen saturation’. For ab-
stract books that did not include keywords, we limited the search
to the relevant sections, such as pulmonology and neonatology.
Data collection and analysis
We used the methods of Cochrane Neonatal for data collection
and analysis.
Selection of studies
LA, BD, and PD independently reviewed the results of the search
and selected studies for inclusion.
Data extraction and management
Weused a data extraction form specifically designed for this review.
We collected information on the following outcome variables:
• composite outcome of death or major disability by 18 to 24
months corrected for gestational age;
• death (to discharge, to 18 to 24 months follow-up);
• major disability by 18 to 24 months corrected for
gestational age;
• ROP treatment by laser photocoagulation, cryotherapy or
bevacizumab treatment (performed if threshold ROP occurs);
• measures of respiratory support, defined as (a) supplemental
oxygen requirement at 36 weeks postmenstrual age, (b) days of
endotracheal intubation, (c) days of CPAP, (d) days of
supplemental oxygen, (e) days on home oxygen; patent ductus
arteriosus requiring medical treatment (defined as using cyclo-
oxygenase inhibitors) or surgical treatment;
• necrotising enterocolitis (trialist defined);
• weight at 36 weeks postmenstrual age, discharge home and
18 and 24 months corrected for gestational age;
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• re-admissions to hospital up to 18 to 24 months corrected
for gestational age;
• cerebral palsy with GMFCS level 2 or higher or MACS
level 2 or higher at 18 to 24 months corrected for gestational age;
• blindness (< 6/60 vision, 1.3 logMAR in both eyes);
• severe hearing loss;
• quantitative Bayley III scores.
We resolved differences in assessment by discussion or by involving
the remaining review authors.
For each study, one review author (LA) extracted, assessed, and
coded all data for each included study and entered final data into
ReviewManager 5 (RevMan 2014). A second review author (RW)
checked these data for accuracy and each of the authors from the
included trials also checked the accuracy of their own trial data.
We resolved discrepancies through discussion. We contacted the
authors of the original reports to provide further details when
information regarding any of the above was unclear.
Assessment of risk of bias in included studies
Weused the standardmethods of CochraneNeonatal. LA andRW
independently assessed the risk of bias for each study using the
criteria outlined in theCochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). RWprepared the initial ’Risk of bias’
tables for discussion. Disagreements were resolved by discussion
or by involving the remaining review authors and members of the
NeOProM Collaboration.
We assessed the methodological quality of the studies using the
following criteria:
• Sequence generation (checking for possible selection bias).
For each included study, we categorised the method used to
generate the allocation sequence as:
◦ low risk (any truly random process, e.g. random
number table; computer random number generator);
◦ high risk (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
◦ unclear risk.
• Allocation concealment (checking for possible selection
bias). For each included study, we categorised the method used
to conceal the allocation sequence as:
◦ low risk (e.g. telephone or central randomisation;
consecutively numbered, sealed, opaque envelopes);
◦ high risk (open random allocation; unsealed or non-
opaque envelopes; alternation; date of birth);
◦ unclear risk.
• Blinding (checking for possible performance bias). For each
included study, we categorised the methods used to blind study
participants and personnel from knowledge of which
intervention a participant received. We assessed blinding
separately for different outcomes or classes of outcomes. We
categorised the methods as:
◦ low risk, high risk or unclear risk for participants;
◦ low risk, high risk or unclear risk for personnel;
◦ low risk, high risk or unclear risk for outcome
assessors.
• Incomplete outcome data (checking for possible attrition
bias through withdrawals, dropouts, protocol deviations). For
each included study and for each outcome, we described the
completeness of data including attrition and exclusions from the
analysis. We noted whether attrition and exclusions were
reported, the numbers included in the analysis at each stage
(compared with the total randomised participants), reasons for
attrition or exclusion where reported, and whether missing data
were balanced across groups or were related to outcomes. We
categorised the methods as:
◦ low risk (less than 20% missing data);
◦ high risk (20% or more missing data);
◦ unclear risk.
• Selective reporting bias. For each included study, we
described how we investigated the possibility of selective outcome
reporting bias and what we found. We assessed the methods as:
◦ low risk (where it is clear that all of the study’s
prespecified outcomes and all expected outcomes of interest to
the review have been reported);
◦ high risk (where not all the study’s prespecified
outcomes have been reported; one or more reported primary
outcomes were not prespecified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
◦ unclear risk.
• Other sources of bias. For each included study, we
described any important concerns we had about other possible
sources of bias (for example, whether there was a potential source
of bias related to the specific study design or whether the trial
was stopped early due to some data-dependent process or interim
analyses issues, or both). We assessed whether each study was free
of other problems that could put it at risk of bias as follows:
◦ low risk;
◦ high risk;
◦ unclear risk.
• Overall risk of bias (described in Table 8.5c in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011)).
We made explicit judgements regarding whether studies were at
high risk of bias, according to the criteria given in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
With reference to (1) to (6) above, we assessed the likelymagnitude
and direction of the bias and whether we considered it is likely to
have an impact on the findings. If need be, we planned to explore
the impact of the level of bias through undertaking sensitivity
analyses (see Sensitivity analysis below).
Measures of treatment effect
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We used the standard methods of Cochrane Neonatal to analyse
data.
Weperformed statistical analyses usingReviewManager 5 software
(RevMan 2014). We analysed dichotomous data using the risk
ratio (RR), risk difference (RD), and the number needed to treat
for an additional beneficial outcome (NNTB) or number needed
to treat for an additional harmful outcome (NNTH).We included
the 95%confidence interval (CI) for all estimates. For the purposes
of the analysis, we considered the lower target range group to be
the treatment or experimental group and the higher target range
group to be the control group.
We analysed continuous data using the mean difference (MD) or
the standardised mean difference (SMD) to combine trials that
measured the same outcome but used different methods.
Unit of analysis issues
The unit of analysis was each infant randomised.
Dealing with missing data
For the included studies we noted levels of attrition. We explored
the impact of including studies with high levels of missing data in
the overall assessment of treatment effect using sensitivity analyses.
We analysed all outcomes on an intention-to-treat basis, i.e. we
included all participants randomised to each group in the analyses.
We did not replace missing data by imputation: the denominator
for each outcome in each trial was the number randomised minus
any participants whose outcomes were known to be missing.
Assessment of heterogeneity
We examined heterogeneity between trials by first assessing dif-
ferences in trial methodologies and clinical heterogeneity. If we
judged clinical heterogeneity to be absent, we then quantified the
impact of heterogeneity using the I² statistic (less than 25%, no
heterogeneity; 25% to 49%, low heterogeneity; 50% to 74%,
moderate heterogeneity; and 75% or more, high heterogeneity)
(Higgins 2003; Higgins 2011). If heterogeneity was detected, we
explored the possible causes of statistical heterogeneity using pre-
specified subgroup analysis (for example, differences in study qual-
ity, participant or intervention characteristics).
Assessment of reporting biases
We assessed possible publication bias and other biases using sym-
metry/asymmetry of funnel plots, if there were sufficient trials to
allow these analyses.
For included trials that were recently performed (and therefore
prospectively registered), we explored possible selective reporting
of study outcomes by comparing the primary and secondary out-
comes in the reports with the primary and secondary outcomes
proposed at trial registration, using the website www.who.int/
ictrp. If we found such discrepancies, we contacted the primary
investigators to interpret variances with outcomes prespecified at
trial registration.
Data synthesis
We conducted the meta-analysis using Review Manager 5 soft-
ware (RevMan 2014), supplied byCochrane.We used theMantel-
Haenszel method for estimates of typical risk ratio and risk dif-
ference. We analysed any continuous measures using the inverse
variance method.We used the fixed-effect model for all meta-anal-
yses.
Quality of evidence
We used the Grading of Recommendations Assessment, Devel-
opment and Evaluation (GRADE) approach, as outlined in the
GRADE Handbook for Grading Quality of Evidence and Strength of
Recommendations (Schünemann 2013), to assess the quality of evi-
dence for the following major outcomes: death or major disability
by 18 to 24 months corrected age (aligned definition); death to 18
to 24 months corrected age; major disability by 18 to 24 months
corrected age (aligned definition); retinopathy of prematurity re-
quiring treatment; necrotising enterocolitis; blindness.
Two authors (LA, RW) independently assessed the quality of the
evidence for each of the outcomes above. The full author group
further considered the ’Risk of bias’ assessments and discussed
these in detail at a NeOProM Collaborators meeting on 29 April
2016 in order to reach consensus. We considered evidence from
randomised controlled trials as high quality but downgraded the
evidence by one level for serious (or by two levels for very serious)
limitations based upon the following: design (risk of bias), consis-
tency across studies, directness of the evidence, precision of esti-
mates and presence of publication bias. We used the GRADEpro
GDT Guideline Development Tool to create a ’Summary of find-
ings’ table to report the quality of the evidence.
The GRADE approach results in an assessment of the quality of
a body of evidence of one of four grades:
• High: We are very confident that the true effect lies close to
that of the estimate of the effect.
• Moderate: We are moderately confident in the effect
estimate: the true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different.
• Low: Our confidence in the effect estimate is limited: the
true effect may be substantially different from the estimate of the
effect.
• Very low: We have very little confidence in the effect
estimate: the true effect is likely to be substantially different from
the estimate of effect.
Subgroup analysis and investigation of heterogeneity
The effect of the intervention (lower versus higher oxygen satu-
ration targeting) may be different due to certain characteristics of
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either the infant or the way the intervention was delivered. If pos-
sible, we explored these effects in the following subgroup analyses.
Participant baseline characteristics
• Gestational age (less than 26 weeks/26 weeks or more)
• Inborn or outborn status
• Antenatal steroids (any: yes/no)
• Sex (male/female)
• Small for gestational age (yes/no)
• Multiples (singleton/multiple)
• Mode of delivery (vaginal/caesarean)
Intervention characteristics
• Oximeter calibration software (original or revised)
We limited subgroup analyses to the primary outcome (death or
major disability), the individual components of the primary out-
come (death, major disability), and two key secondary outcomes
(necrotising enterocolitis, retinopathy of prematurity requiring
treatment). All subgroup analyses were pre-specified before any
meta-analyses of combined data were undertaken.
Sensitivity analysis
We planned sensitivity analyses for situations where this might
affect the interpretation of significant results (for example, where
there are risks of bias associated with the quality of some of the
included trials or missing outcome data).
R E S U L T S
Description of studies
Results of the search
We searched using the search strategy outlined previously from
1940 to 11 April 2016 and identified 3412 potential published
studies and 329 trial registration records. LA and BD screened the
citations and abstracts of these 3741 records in duplicate for the
initial search covering the period 1940 to 14 May 2014, and LA
and PD screened these for the updated search covering the period
from1 January 2014 to11April 2016 (see Figure 1). Therewere no
disagreements regarding study eligibility that required resolution.
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Figure 1. Study flow diagram
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Included studies
We identified five trials meeting the inclusion criteria of the review
(n = 4965 infants) (Vaucher 2012; Schmidt 2013; BOOST NZ
2014; BOOST-II UK 2016; BOOST-II Australia 2016). Details
are included in the Characteristics of included studies table and
Figure 2.
Figure 2. Participant flow chart for the combined five NeOProM trials
The inclusion criteria were similar between trials. All trials enrolled
preterm infants of less than 28 weeks’ gestation, with one speci-
fying a minimum gestation of 24 weeks’ (Vaucher 2012) and an-
other 23 weeks’ (Schmidt 2013). Three trials also required infants
to be less than 24 hours old (Schmidt 2013; BOOST NZ 2014;
BOOST-II Australia 2016), one required the infants to be less
than 12 hours old (or less than 24 hours if outborn) (BOOST-II
UK 2016), and one trial required infants to be enrolled by two
hours of age (Vaucher 2012). In all five trials the intervention and
comparator were the same, i.e. lower oxygen saturation targeting
(SpO 85% to 89%) versus higher oxygen saturation targeting
(SpO 91% to 95%), although recommendations for alarm limit
settings differed between trials (see Characteristics of included
studies table).
Excluded studies
We assessed four studies (one published study, one conference pro-
ceeding, and two trial registration records) in full but excluded
them as they were either not randomised trials or did not fulfil the
other eligibility criteria for the interventions being compared, but
this had not been clear from the title or abstract of the identified
record (see the Characteristics of excluded studies table for the
reasons for these exclusions). There were no other identified on-
going studies or studies awaiting clarification that were potentially
eligible for inclusion.
Risk of bias in included studies
We assessed methodological quality using the criteria of Cochrane
Neonatal and the findings are summarised in Figure 3.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Random sequence generation: all five of the included trials met
this criterion.
Allocation concealment: this was adequate in all five of the trials.
All five trials were judged as having a low risk of bias for this
criterion.
Blinding
Blinding of participants and personnel: this was adequate in all five
of the trials with all using the same masked oximeters (see Figure
4 for a diagramatic representation of how masking was achieved
within the trials).
Figure 4. Oximeter offset to achieve masking as used in the five NeOProM trials
Blinding of outcome assessments: this was adequate in all five of
the trials with outcome assessors remaining masked to treatment
allocation.
All five trials were judged as having a low risk of bias for this
criterion.
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Incomplete outcome data
We assessed incomplete outcome data (attrition bias) as low risk
of bias in all five trials. The primary outcome was a composite
outcome of death or major disability by 18 to 24 months cor-
rected for gestational age. Survival status was known for 97% to
100% of all infants in each trial. Major disability was defined as
severe visual loss, deafness requiring hearing aids, cerebral palsy
by various measures, or as a Bayley-III Developmental Assessment
(BSID-III) cognitive score < 85 and/or language score < 85. There
was variation between trials in the completeness of primary out-
come data gathered according to the BSID-III assessments. By
this measure between 79% and 96% had adequate data for the
analysis of the composite primary outcome within the included
trials (see Characteristics of included studies table). In two trials
(Vaucher 2012 and Schmidt 2013, with 94% and 96% recovered
data respectively), there was no imputation of missing data. In the
three other trials various alternative measures of developmental
status were substituted (BOOSTNZ 2014; BOOST-II UK 2016;
BOOST-II Australia 2016). With this qualification, all trials re-
ported greater than 94% recovery of data for the primary analysis.
These data, with protocol defined and alternative measures, were
used in the definitions of the primary outcome and of major dis-
abilities.
Selective reporting
We assessed selective reporting (reporting bias) as low risk in all five
trials, with all trials reporting their pre-specified primary outcome
and main secondary outcomes, and the trials identified any post
hoc analyses in their trial reports.
Other potential sources of bias
Investigator concerns resulting from the significantly increased
mortality risk with the lower SpO2 target range in the SUPPORT
Trial publication led to an unscheduled safety analysis when 1135
of the planned 1200 (95%) BOOST-II Australia and 973 of the
planned 1200 (81%) BOOST-II UK infants had been recruited
(BOOST-II Australia 2016; BOOST-II UK 2016). A decision
was made to terminate recruitment in both the BOOST-II UK
and BOOST-II Australia trials based on a pre-specified rule. There
was an 8.5% excess in 36-week mortality in the low target group
monitored with oximeters incorporating the revised calibration
software (data pooled from both studies, P < 0.001 with a sig-
nificant treatment by software subgroup interaction, P = 0.006)
(Stenson 2011). The early stopping of these two trials (with 95%
and 81% of their final planned sample sizes at that point) raises
the question of whether this overestimates treatment effect, and
thus the risk of bias was categorised as ’unclear’ for the BOOST-
II UK and BOOST-II Australia trials. The other three trials were
assessed as low risk of bias for this criterion.
Effects of interventions
See: Summary of findings for the main comparison Oxygen
saturation targeting in preterm infants
After considerable discussion between the review authors, we
reached consensus regarding the quality of evidence assessments
and data extraction from the five included trials.
Lower versus higher targeted oxygen saturations (no
subgroups)
For the purpose of these analyses, we considered the lower target
range group the intervention group and we considered the higher
target range group the control group.
The SUPPORT trial used a different Bayley-III cut point (< 70)
and components (composite cognitive score only) as part of their
definition of major disability compared with the other four trials
(which used Bayley-III < 85 on either the composite cognitive or
language scores). The SUPPORT trial provided unpublished out-
come data using the same Bayley-III cut point and components for
inclusion in this review in order to better align the definitions of
major disability across all five trials. For the outcomes where these
data were used, we used the term ’aligned definition’. However, the
definition of major disability was not ’fully’ aligned as each trial
used slightly different methods for assigning an outcome of major
disability. The term ’trialist defined’ used throughout this review
indicates analyses that used data as published in the trial reports.
For the two outcomes where these data are relevant (’death or ma-
jor disability’ and ’major disability’), both the ’aligned definition’
and ’trialist defined’ versions are presented. However, our primary
analyses are based on the meta-analyses of updated data, using the
aligned definition of major disability. The SUPPORT trial also
provided unpublished data for inclusion in this review to align
the definition of ’retinopathy of prematurity requiring treatment’
across all trials.
We graded the quality of evidence for outcomes as high (low risk
of bias, low inconsistency, no indirectness, low imprecision, and
low risk of reporting bias) unless otherwise stated below.
Primary outcome
Death or major disability by 18 to 24 months corrected age
(aligned definition) (outcome 1.1)
Using the aligned definition of this outcome, there was no signif-
icant difference between the groups in the incidence of death or
major disability by 18 to 24 months corrected age (typical risk ra-
tio (RR) 1.04, 95% confidence interval (CI) 0.98 to 1.10; typical
risk difference (RD) 0.02, 95% CI -0.01 to 0.05; 5 trials, 4754
infants; I² = 27%) (high-quality evidence) (Analysis 1.1).
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Death or major disability by 18 to 24 months corrected age
(trialist defined) (outcome 1.2)
The meta-analysis showed a statistically significant increased risk
of death or major disability at 18 to 24 months corrected age for
the lower target group when using the trialists’ own definitions of
major disability (typical RR 1.07, 95% CI 1.00 to 1.14; typical
RD 0.03, 95% CI 0.00 to 0.06; 5 trials, 4751 infants; I² = 1%)
(Analysis 1.2).
Secondary outcomes
Death to 18 to 24 months corrected age (outcome 1.3)
The meta-analysis showed a statistically significant increased risk
of death at 18 to 24 months corrected age for the lower target
group (typical RR 1.16, 95% CI 1.03 to 1.31; typical RD 0.03,
95% CI 0.01 to 0.05; 5 trials, 4873 infants; I² = 0%) (high-
quality evidence) (Analysis 1.3). The number needed to treat for
an additional harmful outcome (NNTH) with lower targeting to
result in one additional death by 18 to 24 months corrected age is
31 (95% CI 16 to 168).
Major disability by 18 to 24 months corrected age (aligned
definition) (outcome 1.4)
There was no significant difference between the groups in the
incidence of major disability by 18 to 24 months corrected age
when using the aligned definition ofmajor disability (seeOutcome
1.2 above) across trials (typical RR 1.01, 95% CI 0.93 to 1.09; 5
trials, 3867 infants; I² = 22%) (high-quality evidence) (Analysis
1.4).
Major disability by 18 to 24 months corrected age (trialist
defined) (outcome 1.5)
There was no significant difference between the groups in the
incidence of major disability by 18 to 24 months corrected age
when using the trialists’ own definitions ofmajor disability (typical
RR 1.04, 95% CI 0.94 to 1.14; 5 trials, 3864 infants; I² = 0%)
(Analysis 1.5).
Death to discharge (outcome 1.6)
The meta-analysis showed a statistically significant increased risk
of death before discharge for the lower target group (typical RR
1.16, 95% CI 1.03 to 1.31; typical RD 0.03, 95% CI 0.00 to
0.05; 5 trials, 4958 infants; I² = 0%) (Analysis 1.6). The NNTH
with lower targeting to result in one additional death to discharge
is 34 (95% CI 17 to 180).
Severe retinopathy of prematurity (ROP) or retinal therapy
(trialists defined) (outcome 1.7)
The meta-analysis showed a statistically significant reduced risk of
severe ROP or retinal therapy for the lower target group (typical
RR 0.72, 95% CI 0.61 to 0.85; typical RD -0.04, 95% CI -0.06
to -0.02; 5 trials, 4089 infants; I² = 69%) (moderate-quality evi-
dence) (Analysis 1.7).We rated the quality of evidence for this out-
come as moderate due to inconsistency (moderate heterogeneity).
The number needed to treat for an additional beneficial outcome
(NNTB) with lower oxygen targeting to prevent one additional
case of severe ROP or retinal therapy is 34 (95% CI 21 to 63).
Patent ductus arteriosus requiring medical or surgical
treatment (outcome 1.8)
There was no significant difference between the groups in the
incidence of patent ductus arteriosus requiring medical or surgical
treatment (typical RR 1.00, 95% CI 0.95 to 1.06; 5 trials, 4928
infants; I² = 0%) (Analysis 1.8).
Necrotising enterocolitis (outcome 1.9)
Three trials (BOOST Australia, NZ, and UK) used a definition
of ’necrotising enterocolitis requiring surgery or leading to death’
for this outcome. The other two trials used either a modified Bell’s
staging (SUPPORT) or surgical or X-ray diagnoses (COT) to de-
fine this outcome. The meta-analysis showed a statistically signifi-
cant increased risk of necrotising enterocolitis for the lower target
group (typical RR 1.24, 95% CI 1.05 to 1.47; typical RD 0.02,
95%CI 0.01 to 0.04; 5 trials, 4929 infants; I² = 0%) (high-quality
evidence) (Analysis 1.9). The NNTH with lower targeting to re-
sult in one additional case of necrotising enterocolitis is 37 (95%
CI 19 to 178).
Cerebral palsy with Gross Motor Functioning Classification
System (GMFCS) level 2 or higher at 18 to 24 months
corrected age (outcome 1.10)
There was no significant difference between the groups in the
incidence of cerebral palsy with GMFCS level 2 or higher at 18 to
24 months corrected age (typical RR 1.02, 95% CI 0.79 to 1.32;
5 trials, 3877 infants; I² = 20%) (Analysis 1.10).
Blindness (outcome 1.11)
There was no significant difference between the groups in the
incidence of blindness (typical RR 1.13, 95% CI 0.65 to 1.97; 5
trials, 3875 infants; I² = 0%) (Analysis 1.11). We rated the quality
of evidence for this outcome as moderate for imprecision due to
low event rates.
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Severe hearing loss (outcome 1.12)
There was no significant difference between the groups in the
incidence of severe hearing loss (typical RR 1.02, 95% CI 0.73 to
1.43; 5 trials, 3869 infants; I² = 0%) (Analysis 1.12). We rated the
quality of evidence for this outcome as moderate for imprecision
due to low event rates.
Proportion of infants re-admitted to hospital up to 18 to 24
months corrected age (outcome 1.13)
There was no significant difference between the groups in the pro-
portion of infants re-admitted to hospital up to 18 to 24 months
corrected age (RR 1.08, 95% CI 0.93 to 1.26; 1 trial, 295 infants;
I² not applicable) (Analysis 1.13).We rated the quality of evidence
for this outcome asmoderate for imprecision as data were available
from only one trial.
Weight (grams) at discharge home (outcome 1.14)
There was no significant difference between the groups in the
weight (grams) of infants at discharge home (mean difference
(MD) -52.00, 95% CI -214.25 to 110.25; P = 0.53; 1 trial, 295
infants; I² not applicable) (Analysis 1.14). We rated the quality
of evidence for this outcome as moderate for imprecision as data
were available from only one trial.
Weight (kilograms) at 18 or 24 months corrected age
(outcome 1.15)
There was no significant difference between the groups in the
weight (grams) of infants at discharge home (MD 0.80, 95% CI -
0.24 to 1.84; 1 trial, 280 infants; I² not applicable) (Analysis 1.15).
We rated the quality of evidence for this outcome as moderate for
imprecision as data were available from only one trial.
Days of endotracheal intubation (outcome 1.16)
There was no significant difference between the groups in days
of endotracheal intubation (MD 0.28, 95% CI -1.16 to 1.72; 2
trials, 1386 infants; I² = 0%) (Analysis 1.16).
Days of continuous positive airway pressure (CPAP)
(outcome 1.17)
There was no significant difference between the groups in days of
CPAP (MD -0.04, 95% CI -1.38 to 1.30; 3 studies, 2526 infants;
I² = 0%) (Analysis 1.17).
Days of supplemental oxygen (outcome 1.18)
The meta-analysis showed a statistically significant reduction in
days of supplemental oxygen for the lower target group (MD -
8.78, 95% CI -12.02 to -5.54; P < 0.00001; 3 trials, 2507 infants;
I² = 4%) (Analysis 1.18).
Supplemental oxygen requirement at 36 weeks
postmenstrual age (outcome 1.19)
This outcome was determined using a physiologic test in the
Vaucher 2012 andBOOST-IIUK2016 trialswhile the other three
trials determined the need for supplemental oxygen at 36 weeks
postmenstrual age using the infant’s assigned study oximeter.
The meta-analysis showed a statistically significant reduced risk
of supplemental oxygen requirement at 36 weeks postmenstrual
age for the lower target group (typical RR 0.87, 95% CI 0.81 to
0.94; typical RD -0.06, 95% CI -0.09 to -0.03; 5 trials, 4175 in-
fants; I² = 44%) (Analysis 1.19). We rated the quality of evidence
for this outcome as moderate due to inconsistency (moderate het-
erogeneity). The NNTB with lower oxygen targeting to prevent
one additional infant receiving supplemental oxygen at 36 weeks
postmenstrual age is 20 (95% CI 14 to 44).
Days on home oxygen (outcome 1.20)
For the infants who went home on supplemental oxygen (n =
237), there was no significant difference between the groups in the
days of home oxygen (MD -24.17, 95% CI -57.99 to 9.66; P =
0.16; 2 trials, 237 infants; I² = 61%) (Analysis 1.20). We rated the
quality of evidence for this outcome as low due to inconsistency
(moderate heterogeneity) and imprecision.
Quantitative Bayley III scores (Composite Cognitive Score
(CCS)) (outcome 1.21)
There was no significant difference between the groups in quanti-
tative Bayley III scores (Composite Cognitive Score (CCS)) (MD
0.55, 95% CI -0.91 to 2.00; P = 0.46; 2 trials, 1892 infants; I² =
0%) (Analysis 1.21).
Quantitative Bayley III scores (Composite Language Score
(CLS)) (outcome 1.22)
There was no significant difference between the groups in quanti-
tative Bayley III scores (Composite Language Score (CLS)) (MD
0.20, 95% CI -2.03 to 2.43; 1 trial, 903 infants; P = 0.86; I² not
applicable) (Analysis 1.22). We rated the quality of evidence for
this outcome as moderate for imprecision as data were available
from only one trial.
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Lower versus higher targeted oxygen saturations
(primary outcome, subgrouped by gestational age)
Death or major disability by 18 to 24 months corrected age
(trialist defined) (outcome 2.1)
There was no statistically significant difference in the incidence
of death or major disability by 18 to 24 months corrected age
(trialist defined) in the subgroup of infants born at < 26 weeks’
gestation (RR 1.09, 95% CI 0.89 to 1.32; 1 trial, 537 infants;
I² not applicable) compared with infants born at ≥ 26 weeks’
gestation (RR 1.17, 95% CI 0.86 to 1.60; 1 trial, 697 infants; I²
not applicable): test for subgroup difference P = 0.69. We rated the
quality of evidence for this outcome as moderate for imprecision
as data were available from only one trial (Analysis 2.1).
Lower versus higher targeted oxygen saturations
(primary outcome, subgrouped by sex)
Death or major disability by 18 to 24 months corrected age
(trialist defined) (outcome 3.1)
There was no statistically significant difference in the incidence
of death or major disability by 18 to 24 months corrected age
(trialist defined) in the subgroup of male infants (RR 1.13, 95%
CI 0.96 to 1.33; 1 trial, 503 infants; I² not applicable) compared
with female infants (RR 1.07, 95% CI 0.87 to 1.31; 1 trial, 438
infants; I² not applicable): test for subgroup difference P = 0.66.
We rated the quality of evidence for this outcome as moderate for
imprecision as data were available from only one trial (Analysis
3.1).
Lower versus higher targeted oxygen saturations
(primary outcome, subgrouped by multiples)
Death or major disability by 18 to 24 months corrected age
(trialist defined) (outcome 4.1)
There was no statistically significant difference in the incidence of
death or major disability by 18 to 24 months corrected age (trialist
defined) in the subgroup of singleton infants (RR 1.10, 95% CI
0.94 to 1.29; 1 trial, 670 infants; I² not applicable) compared with
infants from multiple births (RR 1.11, 95% CI 0.88 to 1.39; 1
trial, 271 infants; I² not applicable): test for subgroup difference
P = 0.94. We rated the quality of evidence for this outcome as
moderate for imprecision as data were available from only one trial
(Analysis 4.1).
Lower versus higher targeted oxygen saturations
(primary outcome, subgrouped by oximeter
calibration software)
Death or major disability by 18 to 24 months corrected age
(aligned definition) (outcome 5.1)
There was no statistically significant difference in the incidence
of death or major disability by 18 to 24 months corrected age
(aligned definition) in the subgroup of infants who used the origi-
nal oximeter calibration algorithm (typical RR 1.00, 95% CI 0.94
to 1.07; 5 trials, 3003 infants; I² = 0%) compared with the infants
who used the revised algorithm (typical RR 1.13, 95% CI 1.02 to
1.24; 3 trials, 1681 infants; I² = 0%): test for subgroup difference
P = 0.06 (Analysis 5.1).
Death or major disability by 18 to 24 months corrected age
(trialist defined) (outcome 5.2)
There was no statistically significant difference in the incidence of
death or major disability by 18 to 24 months corrected age (trialist
defined) in the subgroup of infants who used the original oximeter
calibration algorithm (typical RR 1.04, 95% CI 0.95 to 1.13; 5
trials, 3000 infants; I² = 0%) compared with infants who used the
revised oximeter calibration algorithm (typical RR 1.13, 95% CI
1.02 to 1.24; 3 trials, 1681 infants; I² = 0%): test for subgroup
difference P = 0.24 (Analysis 5.2).
Lower versus higher targeted oxygen saturations
(secondary outcomes, subgrouped by oximeter
calibration software)
Death by 18 to 24 months corrected age (outcome 6.1)
There was a statistically significant difference in the incidence of
death by 18 to 24 months corrected age in the subgroup of in-
fants who used the original oximeter calibration algorithm (typical
RR 1.05, 95% CI 0.91 to 1.22; 5 trials, 3087 infants; I² = 5%)
compared with infants who used the revised oximeter calibration
algorithm (typical RR 1.38, 95% CI 1.13 to 1.68; 3 trials, 1716
infants; I² = 0%): test for subgroup difference P = 0.03 (Analysis
6.1).
Major disability by 18 to 24 months corrected age (aligned
definition) (outcome 6.2)
There was no statistically significant difference in the incidence of
major disability by 18 to 24 months corrected age (aligned defi-
nition) in the subgroup of infants who used the original oximeter
calibration algorithm (typical RR 0.99, 95% CI 0.90 to 1.09; 5
trials, 2529 infants; I² = 40%) compared with infants who used
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the revised oximeter calibration algorithm (typical RR 1.05, 95%
CI 0.91 to 1.22; 3 trials, 1438 infants; I² = 0%): test for subgroup
difference P = 0.49 (Analysis 6.2).
Major disability by 18 to 24 months corrected age (trialist
defined) (outcome 6.3)
There was no statistically significant difference in the incidence
of major disability by 18 to 24 months corrected age (trialist de-
fined) in the subgroup of infants who used the original oximeter
calibration algorithm (typical RR 1.02, 95% CI 0.89 to 1.17; 5
trials, 2526 infants; I² = 30%) compared with infants who used
the revised oximeter calibration algorithm (typical RR 1.05, 95%
CI 0.91 to 1.22; 3 trials, 1438 infants; I² = 0%): test for subgroup
difference P = 0.78 (Analysis 6.3).
Death to discharge (outcome 6.4)
There was a statistically significant difference in the incidence of
death to discharge in the subgroup of infants who used the original
oximeter calibration algorithm (typical RR 1.06, 95% CI 0.90 to
1.26; 4 trials, 2575 infants; I² = 37%) compared with infants who
used the revised oximeter calibration algorithm (typical RR 1.45,
95% CI 1.15 to 1.84; 2 trials, 1182 infants; I² = 0%): test for
subgroup difference P = 0.04 (Analysis 6.4).
Severe retinopathy of prematurity or retinal therapy (trialist
defined) (outcome 6.5)
There was no statistically significant difference in the incidence
of severe retinopathy of prematurity or retinal therapy in the sub-
group of infants who used the original oximeter calibration al-
gorithm (typical RR 0.67, 95% CI 0.53 to 0.84; 4 trials, 2085
infants; I² = 67%) compared with infants who used the revised
oximeter calibration algorithm (typical RR 0.77, 95% CI 0.56 to
1.05; 2 trials, 988 infants; I² = 55%): test for subgroup difference
P = 0.47 (Analysis 6.5).
Lower versus higher targeted oxygen saturations
(secondary outcomes, subgrouped by gestational age)
Death by 18 to 24 months corrected age (outcome 7.1)
There was no statistically significant difference in the incidence of
death by 18 to 24 months corrected age in the subgroup of infants
born at < 26 weeks’ gestation (RR 1.22, 95% CI 0.95 to 1.57;
1 trial, 550 infants; I² = not applicable) compared with infants
born at ≥ 26 weeks’ gestation (RR 1.25, 95% CI 0.84 to 1.86; 1
trial, 731 infants; I² = not applicable): test for subgroup difference
P = 0.91. We rated the quality of evidence for this outcome as
moderate for imprecision as data were available from only one trial
(Analysis 7.1).
Major disability by 18 to 24 months corrected age (trialist
defined) (outcome 7.2)
There was no statistically significant difference in the incidence of
major disability by 18 to 24 months corrected age in the subgroup
of infants born at < 26 weeks’ gestation (RR 0.84, 95% CI 0.52
to 1.37; 1 trial, 367 infants; I² = not applicable) compared with
infants born at ≥ 26 weeks’ gestation (RR 1.07, 95% CI 0.59 to
1.93; 1 trial, 609 infants; I² = not applicable): test for subgroup
difference P = 0.54. We rated the quality of evidence for this
outcome as moderate for imprecision as data were available from
only one trial (Analysis 7.2).
D I S C U S S I O N
Summary of main results
When compared to targeting a higher oxygen saturation range
(SpO 91% to 95%) from soon after birth in extremely preterm
infants, targeting a lower oxygen saturation range (SpO 85%
to 89%) had no significant effect on the primary composite out-
come of death ormajor disability (using an aligned definition) (P =
0.18), but significantly increased the incidence of death at 18 to 24
months corrected age (P = 0.01), death before hospital discharge
(P = 0.02), and necrotising enterocolitis (P = 0.01). Targeting the
lower range significantly decreased the rate of severe or treated
retinopathy of prematurity (ROP) (P = 0.004) and supplemental
oxygen use at 36 weeks postmenstrual age (P = 0.0002), but had
no significant effect on blindness (P = 0.65), patent ductus arte-
riosus requiring treatment (P = 0.87), or major disability (when
an aligned definition across trials was used) at 18 to 24 months
corrected age (P = 0.80).
Subgroup analyses ofmajor outcomes by oximeter calibration soft-
ware (original versus revised) showed a statistically significant dif-
ference in death by 18 to 24 months corrected age: original al-
gorithm (P = 0.52) versus revised algorithm (P = 0.001) (test for
subgroup difference P = 0.03). A similar result was seen for death
before hospital discharge (test for subgroup difference P = 0.04).
There were no other participant or intervention characteristics
within the pre-specified subgroup analyses that showed significant
differences in the treatment effect, although data for many are not
yet currently available from the published trials.
The five trials included in this review were prospectively planned
to be similar with regards to the enrolled participants, the inter-
ventions compared, and the outcomes measured and they were
designed to be included in a meta-analysis once the individual tri-
als were completed. As would thus be expected, the heterogeneity
seen across the trials for most outcomes was low. Similarly there
was an overall low risk of bias across all five trials. In the meta-
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analysis the combined sample size of 4965 provides high-quality,
robust evidence for important outcomes with regards to oxygen
saturation targeting in extremely preterm infants.
Overall completeness and applicability of
evidence
Data were available and complete from all five included trials
for the primary outcome (death or major disability at 18 to 24
months corrected age), and the components of the primary out-
come: death, major disability, cerebral palsy, blindness, and se-
vere hearing loss, as well as other important neonatal outcomes
including death before hospital discharge, severe ROP, patent duc-
tus arteriosus requiring treatment, and necrotising enterocolitis.
Upon request, trialists provided unpublished data (SUPPORT for
retinopathy requiring treatment and major disability with defini-
tion aligned with the other trials, and COT for death before dis-
charge) to improve the completeness of the included data for the
major outcomes.
Other secondary outcomes (1.13 to 1.23) and subgroup analyses
(small for gestational age, multiples, antenatal steroids, inborn sta-
tus) data are either incomplete or not available from the current
trial publications. The included trials are all members of theNeO-
ProM Collaboration, which is currently collating and analysing
the individual participant data (IPD) from all five trials, including
data for the outcomes pre-specified, but not yet available in this
review. It is anticipated that once the NeOProM analyses have
been published, this review will be updated with the additional
information.
Supplemental oxygen delivery and monitoring in extremely
preterm infants in the first days/weeks of life can be particu-
larly challenging. How well a target oxygen saturation range is
maintained is dependent on many factors including infant sta-
bility, alarm limit settings and compliance with these settings,
pulse oximeter properties (e.g. averaging times, alarm trigger delay
times), and nursing staff ratios and experience levels, all of which
can contribute to alarm burden/fatigue. It should be noted that
the trials included in this review did not specifically assess the ef-
fects of actual target ranges achieved, they assessed the intention
to target one of two oxygen saturation ranges. It should also be
re-iterated that the included trials assessed the effect of different
targeting policies, not the effects of different alarm settings. Fu-
ture technologies, such as automated oxygen titration, and more
complex alarm strategies, such as variations in alarm escalation
regimes and cell phone notifications, may all contribute to how
well a desired target range is maintained for an individual infant.
However, until we have better monitoring systems that accurately
provide information regarding tissue oxygenation, we will need
to continue to rely on thorough review of oxygen saturation his-
tograms to better target oxygen saturation in extremely preterm
infants.
The reasons for the difference in mortality seen when oximeters
with the original calibration software, compared to the revised
software, were used cannot be explained simply with the currently
available data. Further exploration of oximeter saturation data
from the five NeOProM trials will be needed to assess whether this
difference was due to the change in oximeter software resulting in
more effective targeting of SpO , whether trial centres became
more effective at targeting SpO over time, or whether there are
other explanations for the differences seen. Until further analyses
are undertaken, the best estimate of the effects of different target
ranges should be focused on the combined results from all trials.
Quality of the evidence
Overall, we assessed all five included trials as being at low risk of
bias (see Characteristics of included studies) as all employed ran-
dom sequence generation, had adequate allocation concealment,
were blinded to participants, personnel and outcome assessors, had
low levels of missing data, and have (or will have, within the NeO-
ProM analyses) reported all pre-specified outcomes (low risk of
reporting bias). Although data are currently unavailable for some
of the secondary and subgroup analyses, we have not downgraded
these outcomes for ’missingness’ as they are known to be available
and will be included in updated versions of this review once the
NeOProM analyses are available.
As noted previously, this prospectively planned meta-analysis has
low levels of statistical heterogeneity (inconsistency) for most out-
comes. The ’severe retinopathy of prematurity or retinal therapy’
outcome had a moderate level of heterogeneity (I² = 69%), which
resulted from the substantially larger treatment effect of lower tar-
geting on this outcome in the SUPPORT trial. Reasons for the
larger treatment effect for this outcome seen in the SUPPORT
trial need to be further explored, possibly by examining ’achieved’
(rather than ’intended’) saturation patterns across trials. The other
outcome that had amoderate level of heterogeneity (I² = 44%) was
’supplemental oxygen at 36 weeks postmenstrual age’. There were
differences between the trials in how the need for supplemental
oxygen at 36 weeks was assessed, with two trials (SUPPORT and
BOOST-II UK) using a physiologic test to determine this need,
while the other three trials did not use such a test. The outcomes
of blindness (1.11) and severe hearing loss (1.12) had low event
rates (43 and 131 events respectively from 3870 infants) so while
there was no heterogeneity seen for these outcomes (I² = 0% for
both), we downgraded both for imprecision due to the resulting
wide 95% confidence intervals.
Despite being well planned and conducted, all five trials each only
achieved a 2% to 3% difference in median oxygen saturations be-
tween the two treatment groups. There was also variability (clinical
heterogeneity) between trials in the oximeter alarm settings (see
Characteristics of included studies table) and in achieved SpO
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distributions.
All five trials directly assessed the same comparisons (SpO 85%
to 89% versus 91% to 95%) and the combined sample size of
over 3800 for all the main outcomes resulted in the quality of
evidence remaining graded as high with regards to the indirectness
and imprecision criteria.
Given the above quality assessments, for the main outcomes (pri-
mary outcomes 1.1. and 1.2 and key secondary outcomes 1.3 to
1.12) more evidence is unlikely to change our confidence in the
estimates of the effects, and these outcomes are thus graded as
high-quality overall.
Other secondary outcomes (1.13 to 1.23) and subgroup analy-
ses (small for gestational age, multiples, antenatal steroids, inborn
status) data are either incomplete or not available from the cur-
rent trial publications resulting in grading the evidence as moder-
ate for these outcomes at present. Further planned evidence from
the NeOProMCollaboration will likely change this assessment of
moderate quality for these outcomes in the near future.
Potential biases in the review process
The inclusion of representatives from the five included trials, the
NeOProM Collaboration, and an independent author in the re-
view team meant that there was considerable debate, discussion,
and difference of opinion regarding many issues covered within
this review. Where consensus could not be reached within the au-
thor team regarding the interpretation of the review’s findings us-
ing the methods outlined, we have included the differing views.
Agreements and disagreements with other
studies or reviews
The data included in this Cochrane Review allow the most com-
plete meta-analysis of the five NeOProM trials published to date,
including unpublished information sourced directly from the tri-
alists for the ’aligned’ definition of major disability-related out-
comes (Analysis 1.1; Analysis 1.4) and treated ROP (Analysis 1.7),
thereby superceding the previous meta-analyses by Manja 2017,
Manja 2015, Saugstad 2014, Fang 2016 and Stenson 2016. This
review was undertaken with direct input from the investigators
whose trials were included, and involved extensive discussion and
consultation. An author independent of the trialists and the NeO-
ProM Collaboration (MV) provided additional input and was
available to resolve disagreements when necessary. The resulting
Characteristics of included studies table, including the ’Risk of
bias’ assessments, are thus based on detailed information sourced
directly from the trialists, which was not available to the authors
of the other published reviews. These assessments of the quality
of evidence (high to moderate) and strength of recommendations
(GRADE criteria) thus differ from those published byManja 2015
(moderate to low).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
When using an aligned definition for major disability, this meta-
analysis of five randomised trials found no significant difference
in the primary composite outcome of death or major disability in
extremely preterm infants when targeting a lower (SpO 85%
to 89%) versus higher (SpO 91% to 95%) oxygen saturation
range. Compared with a higher target range, a lower target range
significantly increased the incidence of death (at both discharge
and 18 to 24 months corrected age) and necrotising enterocolitis.
Conversely, targeting the lower range significantly decreased the
incidence of severe or treated retinopathy of prematurity. There
were no significant differences between the two treatment groups
for major disability including blindness, severe hearing loss, cere-
bral palsy or other important neonatal morbidities. A pre-spec-
ified subgroup analysis of major outcomes by type of oximeter
calibration software (original versus revised) found a significant
difference in the treatment effect between the two software types
for death, with a significantly larger treatment effect seen for those
infants using the revised calibration software. There were no other
significant differences in treatment effect in any of the pre-speci-
fied subgroup analyses, although data for many of these analyses
are not available within the published trial reports.
The size of the observed treatment effects found in this meta-
analysis give estimates that for every 31 to 40 extremely preterm
infants targeted at a lower oxygen range, on average there would
be one additional death and one additional case of necrotising en-
terocolitis, but there would be one less infant with severe/treated
ROP, and eight less days of oxygen exposure per patient. The treat-
ment effect estimates found in this review show the relative effects
of the different target ranges on outcomes. The number needed
to treat for an additional beneficial/harmful outcome (NNTB/
NNTH) estimates included in this review are based on the abso-
lute risk reductions found within the included trials. Whilst the
baseline risks for each of these outcomes may differ in different
settings, and thus trade-offs between the benefits and harms of
the different target ranges can be assessed at a local level (Schmidt
2014), the combined data included in this review constitute the
largest dataset as yet compiled to address this clinical question. As
such, these results provide important information for clinicians,
researchers, parents, and other stakeholders to make judgements
regarding the choice of oxygen saturation targets. It should, how-
ever, be noted that the findings of this meta-analysis should not
be extrapolated to oxygen saturation ranges, or practice settings,
outside those tested within the included trials. Similarly, data from
this review do not provide evidence of an ability to personalise
oxygen saturation targets for individual infants.
Recent guidance from the American Academy of Pediatrics Com-
mittee on Fetus and Newborn advises that “recent RCTs suggest
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that a targeted oxygen saturation range of 90% to 95% may be
safer than 85% to 89%” (Cummings 2016). The results from this
review concur with this conclusion.
Implications for research
Further meta-analyses using individual participants from the
NeOProMCollaboration will provide data for the remaining sec-
ondary outcomes and planned subgroup analyses.
More detailed examination of the included trials’ pulse oximetry
data (either individually or collectively) will be important to ascer-
tain why such a small change in the target range (of approximately
2% to 3% saturation points) produced the significant differences
in important outcomes, such as death and necrotising enterocol-
itis, which were seen. This could include investigation of poten-
tial effect modifying factors such as the proportion of time spent
at lower SpO levels, or other combinations of participant- and
intervention-level factors. The implications for nursing practice
when implementing these findings in practice may warrant fur-
ther study, including the potential for new technologies such as
automated inspired oxygen adjustment, the effects of nursing staff
ratios, and alarm policies.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by year of study]
Vaucher 2012
Methods Randomised, multicentre (USA) trial with a 2-by-2 factorial design
Participants 1316 infants born between 24 weeks 0 days and 27 weeks 6 days of gestation. Infants
were enrolled prior to birth and were thus all inborn at a trial centre. Enrollment was
undertaken from February 2005 until February 2009. Follow-up assessments began in
November 2006 and ended in July 2011
Interventions Infants were monitored with target ranges of oxygen saturation of 85% to 89% or 91%
to 95% using oximeters with concealed saturation offsets of +3% in actual range 85%
to 92% (low target) and -3% in range 88% to 95% (high target), with true readings
displayed 84% and below and 96% and above (see Figure 4). Caregivers were asked
to adjust the concentration of oxygen to maintain displayed saturations between 88%
and 92% when the infant was receiving supplemental oxygen. Alarms were suggested
to be set so that an alarm would sound at displayed saturation values of 85% and 95%,
but they could be changed for individual patients. Infants were also randomly assigned
to continuous positive airway pressure or intubation and surfactant. Intervention was
initiated within 2 hours of birth and continued until 36 weeks of postmenstrual age or
until the infant was breathing ambient air, whichever occurred first. Infants who were
returned to supplemental oxygen were reassigned to the study oximeter. All infants in
this trial were managed with oximeters using the original calibration software
Outcomes Co-primary outcomes: survival at discharge fromhospital without severe ROP (threshold
ROP and/or the need for surgical intervention) assessed until diagnosis or resolution; and
death or survival with neurodevelopmental impairment at 18 to 22 months corrected
age
Neurodevelopmental impairment was defined as having any of the following:
* BSID-III cognitive or language score < 70
* GMFCS level 2 or higher
* Moderate to severe cerebral palsy
* Hearing impairment
* Bilateral visual impairment
Secondary outcomes: severe retinopathy of prematurity, death before discharge, death
by 36 weeks postmenstrual age, BPD defined by use of supplemental oxygen at 36
weeks, BPD physiological definition at 36 weeks, intraventricular haemorrhage grade 3
or 4, periventricular leukomalacia, necrotising enterocolitis stage ≥ 2, pneumothorax,
postnatal corticosteroids for BPD, death by 7 days, death by 14 days, late-onset sepsis,
patent ductus arteriosus requiring medical treatment, patent ductus arteriosus requiring
surgical treatment, any air leaks in first 14 days
Notes Funded by: the USA Eunice Kennedy Shriver National Institute of Child Health and
Human Development; the National Heart, Lung and Blood Institute; and the National
Institutes of Health
Trial registration ID: NCT00233324
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Vaucher 2012 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Permuted-block randomisation was used,
with stratification according to study centre
and gestational age (24 weeks 0 days to 25
weeks 6 days or 26weeks 0 days to 27weeks
6 days). Multiple births were randomised
to the same group
Allocation concealment (selection bias) Low risk Sealed, sequentially numbered with central
tracking opaque envelopes. Oximeter allo-
cation was identifiable (via colour-coded
dots) to designated research staff but not
to clinical staff. Bedside adjustment of sup-
plemental oxygen was performed only by
clinical staff
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding was maintained by oximeter de-
sign.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Parents and assessors were unaware of allo-
cation.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Of the 1316 infants enrolled, 1234 (93.
8%) had adequate data for the analysis of
the composite primary outcome at 18 to
22 months corrected age
35 infants were of unknown status (21 low
target group, 14 high target group) and 47
had incomplete or no follow-up (21 low
target group, 26 high target group). If Bay-
ley scores were missing, children were ex-
cluded from the primary outcome analysis
No participants were excluded after ran-
domisation. All outcome analyses followed
the principle of intention-to-treat. The fol-
low-up rate and the mean corrected age at
neurodevelopmental assessment were sim-
ilar for all treatment groups (in the 2-by-2
factorial design)
Selective reporting (reporting bias) Low risk The predetermined sample size of 1310 in-
fants was achieved. The original study pro-
tocol specified a composite primary out-
come of death before 36 weeks of post-
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Vaucher 2012 (Continued)
menstrual age or severe ROP, but this was
changed to death before discharge or se-
vereROPbefore any data analyseswere per-
formed. All other outcomes pre-specified
in the registration record were reported, in-
cluding assessment of the need for oxygen
at 36 weeks postmenstrual age and safety
outcomes
Other bias Low risk The baseline characteristics of the 2 treat-
ment groups were similar
Schmidt 2013
Methods Randomised, multicentre (Canada, USA, Argentina, Finland, Germany, and Israel) trial
Participants 1201 infants born with gestational ages of 23 weeks 0 days through 27 weeks 6 days,
enrolled within 24 hours after birth, and either born in or transferred into a trial NICU.
Enrollment was undertaken from December 2006 until August 2010. Follow-up assess-
ments began in October 2008 and ended in August 2012
Interventions Infants were monitored with target ranges of oxygen saturation of 85% to 89% or 91%
to 95% using oximeters with concealed saturation offsets of +3% in actual range 85%
to 92% (low target) and -3% in range 88% to 95% (high target), with true readings
displayed 84% and below and 96% and above (see Figure 4). Caregivers were asked
to adjust the concentration of oxygen to maintain displayed saturations between 88%
and 92% when the infant was receiving supplemental oxygen. Alarms were set so that
an alarm would sound at displayed saturation values of 86% and 94%. Intervention
was initiated within 24 hours of birth and continued until 36 weeks of postmenstrual
age irrespective of supplemental oxygen therapy, and until 40 weeks in infants receiving
oxygen therapy at 35 weeks. The oximeters used in this trial were modified with a
revised calibration software in early 2009. 47% of infants in this trial were managed with
oximeters using the original calibration software, 47% with oximeters using the revised
calibration software, and 6% were exposed to both
Outcomes Primary outcome: death or survival with major disability at 18 to 21 months corrected
age.
Major disability was defined as having any of the following:
* Cognitive score < 85 or language score < 85 on BSID-III
* Severe visual loss
* Cerebral palsy with GMFCS level 2 or higher
* Deafness requiring hearing aids
Secondary outcomes: retinopathy of prematurity, brain injury, patent ductus arterious,
necrotising enterocolitis, bronchopulmonary dysplasia, duration of use of positive airway
pressure and supplemental oxygen, hospital re-admissions for respiratory disease, chronic
use of respiratorymedications, andmean composite cognitive, language andmotor scores
31Effects of targeting lower versus higher arterial oxygen saturations on death or disability in preterm infants (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Schmidt 2013 (Continued)
Notes Funded by Canadian Institutes of Health Research
Trial registration ID: ISRCTN62491227, NCT00637169
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computer-generated
randomisation scheme at a remote co-ordi-
nating centre assigned the infants to treat-
ment groups in a 1:1 ratio. Randomisation
was stratified by study centre and balanced
within randomly sized blocks of 2 or 4 pa-
tients. Siblings within multiple births were
randomised individually
Allocation concealment (selection bias) Low risk Study oximeters were labelled with sequen-
tial participant numbers according to the
randomisation scheme. The allocation re-
mained unknown to the members of the
clinical and research teams and all staff at
the co-ordinating centre
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding was maintained by oximeter de-
sign. There is evidence that the algorithm
used for blinding caused a difference in
nursing behaviour with high versus low
oximeters, which reduced separation and
which could have resulted in detection or
co-intervention bias
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Parents and assessors were unaware of allo-
cation.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Of the 1201 infants enrolled, 1147 (95.
5%) had adequate data for the analysis of
the composite primary outcome at 18 to
21 months corrected age
39 infants were of unknown status (17 low
target group, 22 high target group) and 15
had incomplete or no follow-up (7 low tar-
get group, 8 high target group). If Bayley
scores weremissing, childrenwere excluded
from the primary outcome analysis
No participants were excluded after ran-
domisation. All outcome analyses followed
the principle of intention-to-treat. The fol-
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Schmidt 2013 (Continued)
low-up rate and the mean corrected age at
neurodevelopmental assessment were sim-
ilar for both treatment groups
Selective reporting (reporting bias) Low risk The predetermined sample size of 1201 in-
fants was achieved. All outcomes pre-speci-
fied in the registration record were reported
Other bias Low risk There were imbalances in surfactant ad-
ministration and in oxygen therapy be-
fore randomisation. Otherwise the baseline
characteristics were similar in both groups
BOOST NZ 2014
Methods Randomised, multicentre (New Zealand) trial.
Participants 340 infants born at less than 28 weeks’ gestation, enrolled within 24 hours after birth,
and either born in or transferred into a trial NICU. Enrollment was undertaken from
September 2006 until December 2009. Follow-up assessments began in March 2009
and ended in June 2012
Interventions Infants were monitored with target ranges of oxygen saturation of 85% to 89% or 91%
to 95% using oximeters with concealed saturation offsets of +3% in actual range 85%
to 92% (low target) and -3% in range 88% to 95% (high target), with true readings
displayed 84% and below and 96% and above (see Figure 4). Caregivers were asked
to adjust the concentration of oxygen to maintain displayed saturations between 88%
and 92% when the infant was receiving supplemental oxygen. Alarm limits were rec-
ommended (but not mandated) to be set so that an alarm would sound at displayed
saturation values of 87% and 93%. Intervention was initiated within 24 hours of birth,
continued for at least two weeks and was discontinued when infants no longer required
oxygen (pre-specified definition) or otherwise at 36 weeks. All infants in this trial were
managed with oximeters using the original calibration software
Outcomes Primary outcome: death or survival with major disability at 24 months corrected age.
Major disability was defined as having any of the following:
* Cognitive score < 85 or language score < 85 on BSID-III, or MDI < 70 on the BSID-
II assessment
* Severe visual loss
* Cerebral palsy defined as GMFCS level 2 or higher
* Deafness requiring hearing aids
In 33 infantswhere Bayley scoreswere unavailable and therewere noother events defining
major disability, an alternative definition of disability (use of < 10 words) was used
Secondary outcomes: severe ROP (≥ stage 3, or retinal surgery), oxygen dependency
or respiratory support at 36 weeks’ gestational age, days of continuous positive airway
pressure, days of endotracheal intubation, days of oxygenation in both hospital and
days at home, a patent ductus arteriosus diagnosed by echocardiography and requiring
treatment, necrotising enterocolitis requiring surgery or a cause of death, weight at 2
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BOOST NZ 2014 (Continued)
years’ corrected age, readmissions to hospital by 2 years’ corrected age, any respiratory
illness (home oxygen, asthma, chest symptomsmore than once aweek) between discharge
and 2 years, cerebral palsy, mean cognition score and mean language score on BSID-III,
brain injury (intraventricular haemorrhage ≥ grade 3, periventricular leukomalacia, or
porencephalic cysts or contributing to death), and death from pulmonary causes from 4
weeks of age to 2 years’ corrected age
Notes Funded by: NewZealandHeath Research Council and the Child Health Research Foun-
dation (Cure Kids)
Trial registration ID: ACTRN12605000253606
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation lists
were prepared by an independent statisti-
cian. Stratification was by NICU, sex, ges-
tation < 26 or ≥ 26 weeks, and inborn
or outborn. Siblings within multiple births
were randomised individually
Allocation concealment (selection bias) Low risk Central telephone randomisation by inde-
pendent statistician.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding was maintained by oximeter de-
sign.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Parents and assessors were unaware of allo-
cation.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Of the 340 infants enrolled, 335 (98.5%)
had adequate data for the analysis of the
composite primary outcome at 24 months
corrected age
No infants were of unknown status and 5
had incomplete or no follow-up (3 low tar-
get group, 2high target group).WhereBay-
ley scores were missing in a child without
cerebral palsy, blindness, or deafness, “ma-
jor disability” was defined as < 10 words by
parent report at the paediatric assessment
(n = 33 children). If none of these data were
available, the primary endpoint was con-
sidered missing
No participants were excluded after ran-
domisation. All outcome analyses followed
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BOOST NZ 2014 (Continued)
the principle of intention-to-treat. The fol-
low-up rate and the mean corrected age at
neurodevelopmental assessment were sim-
ilar for both treatment groups
Selective reporting (reporting bias) Low risk The predetermined sample size of 320 in-
fants was exceeded, with a final sample size
of 340 being achieved. All outcomes pre-
specified in the registration record were re-
ported
Other bias Low risk The baseline characteristics of the 2 treat-
ment groups were similar
BOOST-II Australia 2016
Methods Randomised, multicentre (Australia) trial.
Participants 1135 infants born at less than 28 weeks’ gestation, enrolled within 24 hours after birth,
and either born in or transferred into a trial NICU. Enrollment was undertaken from
March 2006 until December 2010. Follow-up assessments began in August 2008 and
ended in August 2013
Interventions Infants were monitored with target ranges of oxygen saturation of 85% to 89% or 91%
to 95% using oximeters with concealed saturation offsets of +3% in actual range 85%
to 92% (low target) and -3% in range 88% to 95% (high target), with true readings
displayed 84% and below and 96% and above (see Figure 4). Caregivers were asked
to adjust the concentration of oxygen to maintain displayed saturations between 88%
and 92% when the infant was receiving supplemental oxygen. Alarm limits were recom-
mended to be set so that an alarm would sound at displayed saturation values of 86%
and 94%. Intervention was initiated within 24 hours of birth and discontinued when
infants no longer required oxygen (pre-specified definition) or otherwise at 36 weeks.
Infants whowere returned to supplemental oxygenwere reassigned to the study oximeter.
The oximeters used in this trial were modified with a revised calibration algorithm in
early 2009. 62% of infants in this trial were managed with oximeters with the original
calibration algorithm and 38% with oximeters using the revised calibration algorithm
Outcomes Primary outcome: death or survival with major disability at 24 months corrected age.
Major disability was defined as having any of the following:
* Cognitive score < 85 or language score < 85 on BSID-III
* Severe visual loss
* Cerebral palsy with inability to walk at 2 years corrected age
* Deafness requiring hearing aids
In 85 infants where Bayley scores were unavailable and there were no other events
definingmajor disability, an alternative definition of disability (use of < 10words, delayed
development < 12 months, other severe impairment) was used
Secondary outcomes: death at discharge, death at 36 weeks’ postmenstrual age, treated
retinopathy of prematurity, necrotising enterocolitis requiring surgery or leading todeath,
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BOOST-II Australia 2016 (Continued)
severe intraventricular haemorrhage (≥ grade 3), other brain injury, patent ductus arte-
rious (requiring medical or surgical treatment), oxygen dependency at 36 weeks’ post-
menstrual age, bronchopulmonary dysplasia (physiological definition)
Notes Funded by the Australian National Health and Medical Research Council
Trial registration ID: ACTRN12605000055606
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation lists
were prepared by an independent statisti-
cian and were stratified according to sex,
gestational age, centre, single birth or mul-
tiple births, and whether birth took place
in the hospital where enrolment took place.
Siblings within multiple births were ran-
domised individually
Allocation concealment (selection bias) Low risk Central telephone randomisation by inde-
pendent statistician.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding was maintained by oximeter de-
sign.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Parents and assessors were unaware of allo-
cation.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Of the 1135 infants enrolled, 1094 (96.
4%) had adequate data for the analysis
of the composite primary outcome at 24
months corrected age
12 infants were of unknown status (7 low
target group, 5 high target group) and 29
had incomplete or no follow-up (12 low
target group, 17 high target group). When
Bayley III scores were missing, alternative
measures of disability were used, including
Bayley II scales, paediatric health status as-
sessment, or a Short Health Status Ques-
tionnaire collected via phone call to parents
or a GP visit (n = 85 children). If none of
these data were available, the primary end-
point was considered missing
No participants were excluded after ran-
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BOOST-II Australia 2016 (Continued)
domisation. All outcome analyses followed
the principle of intention-to-treat. The fol-
low-up rate and the mean corrected age at
neurodevelopmental assessment were sim-
ilar for both treatment groups
Selective reporting (reporting bias) Low risk All outcomes pre-specified in the registra-
tion record were reported
Other bias Unclear risk Investigator concerns resulting from the
significantly increased mortality risk with
the lower SpO2 target range in the SUP-
PORT Trial publication led to an un-
scheduled safety analysis when 1135 of the
planned 1200 infants (95%) had been re-
cruited. A decision was made to terminate
recruitment in both the BOOST-II UK
and BOOST-II Australia trials based on a
pre-specified rule. There was an 8.5% ex-
cess in 36-week mortality in the low tar-
get group monitored with an oximeter in-
corporating the revised calibration software
(data pooled from both studies, P < 0.001
with a significant treatment by software
subgroup interaction, P = 0.006). The early
stopping of the trial (with 81% of the fi-
nal planned sample size at that point) raises
the question of whether this overestimates
treatment effect
BOOST-II UK 2016
Methods Randomised, multicentre (UK) trial.
Participants 973 infants born at less than 28 weeks’ gestation, enrolled within 24 hours after birth,
and either born in or transferred into a trial NICU. Enrollment was undertaken from
September 2007 until December 2010. Follow-up assessments began inDecember 2009
and ended in August 2014
Interventions Infants were monitored with target ranges of oxygen saturation of 85% to 89% or 91%
to 95% using oximeters with concealed saturation offsets of +3% in actual range 85%
to 92% (low target) and -3% in range 88% to 95% (high target), with true readings
displayed 84% and below and 96% and above (see Figure 4). Caregivers were asked
to adjust the concentration of oxygen to maintain displayed saturations between 88%
and 92% when the infant was receiving supplemental oxygen. Upper alarm limits were
recommended to be set so that an alarm would sound at a displayed saturation value of
94%. No lower alarm limit was specified. Intervention was initiated within 24 hours of
birth and discontinued when infants no longer required oxygen (pre-specified definition)
or otherwise at 36 weeks. Infants who were returned to supplemental oxygen were
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BOOST-II UK 2016 (Continued)
reassigned to the study oximeter. The oximeters used in this trial were modified with
a revised calibration in early 2009. 23% of infants in this trial were managed with
oximeters using the original calibration software, and 77% with oximeters using the
revised calibration software
Outcomes Primary outcome: death or survival with major disability at 24 months corrected age.
Major disability was defined as having any of the following:
* Cognitive score < 85 or language score < 85 on BSID-III
* Severe visual loss
* Cerebral palsy with inability to walk at 2 years corrected age
* Deafness requiring (or too severe to benefit from) hearing aids
In 176 infants where Bayley scores were unavailable and there were no other events
defining major disability, an alternative definition of disability (incomplete BSID-III
score, Denver Developmental Screening Test, Griffiths Mental Development Scales,
Schedule ofGrowingSkills,WPPS-III, PARCA-R, paediatric assessment,GP assessment,
parental report review of all data) was used
Secondary outcomes: death at discharge, death at 36 weeks’ postmenstrual age, treated
retinopathy of prematurity, necrotising enterocolitis requiring surgery or leading todeath,
severe intraventricular haemorrhage (≥ grade 3), other brain injury, patent ductus arte-
rious (requiring medical or surgical treatment), oxygen dependency at 36 weeks’ post-
menstrual age, bronchopulmonary dysplasia (physiological definition)
Notes Funded by theUKMedical ResearchCouncil andmanaged by theUKNational Institute
for Health Research
Trial registration ID: ISRCTN00842661
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computer-generated minimisation procedure
was used to balance study group assignment ac-
cording to sex, gestational age, and centre. Sib-
lings withinmultiple births were randomised in-
dividually
Allocation concealment (selection bias) Low risk Central randomisation by computer.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding was maintained by oximeter design.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Parents and assessors were unaware of allocation.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Of the 973 infants enrolled, 941 (96.7%) had
adequate data for the analysis of the composite
primary outcome at 24 months corrected age
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6 infants were of unknown status (2 low tar-
get group, 4 high target group) and 26 had in-
complete or no follow-up (11 low target group,
15 high target group). When Bayley III scores
were missing, alternative measures of disability
were used, including Bayley II scales, paediatric
health status assessment, or a Short Health Sta-
tusQuestionnaire collected via phone call to par-
ents or a GP visit (n = 176 children). If none of
these data were available, the primary endpoint
was considered missing
No participants were excluded after randomisa-
tion. All outcome analyses followed the principle
of intention-to-treat. The follow-up rate and the
mean corrected age at neurodevelopmental as-
sessment were similar for both treatment groups
Selective reporting (reporting bias) Low risk All outcomes pre-specified in the registration
record were reported
Other bias Unclear risk Investigator concerns resulting from the signif-
icantly increased mortality risk with the lower
SpO2 target range in the SUPPORT Trial pub-
lication led to an unscheduled safety analysis
when 973 of the planned 1200 infants (81%)
had been recruited. A decision was made to
terminate recruitment in both the BOOST-II
UK and BOOST-II Australia trials based on
a pre-specified rule. There was an 8.5% excess
in 36-week mortality in the low target group
monitored with an oximeter incorporating the
revised calibration software (data pooled from
both studies, P < 0.001 with a significant treat-
ment by software subgroup interaction, P = 0.
006). The early stopping of the trial (with 81%
of the final planned sample size at that point)
raises the question of whether this overestimates
treatment effect
BPD: Bronchopulomary dysplasia
BSID-III: Bayley Scale of Infant Development-version 3
GMFCS: Gross Motor Functioning Classification System
GP: general practitioner
MDI: Mental Developmental Index
NICU: neonatal intensive care unit
ROP: retinopathy of prematurity
PARCA-R: Parent Report of Children’s Abilities-Revised questionnaire
WPPS-III: Wechsler Preschool and Primary Scale of Intelligence-version 3
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Arora 2013 Not a randomised controlled trial. This was a ’before and after’ study of a change in policy
Bard 1996 Not a randomised controlled trial.
NCT00845624 Not a randomised controlled trial. This is a prospective cohort study to determine if time spent out of the targeted
oxygen saturation range in preterm infants is associated with long-term outcomes such as ROP. Planned to enrol
102 preterm infants < 1500 grams or 32 weeks’ gestation
NCT01590316 Intervention not targeting higher or lower oxygen. This is a randomised, blinded, multinational, phase II feasibility
clinical trial involving 165 preterm infants born at gestational ages of up to 27 weeks and 6 days, assessing the
effect of viewing/not viewing cerebral NIRS oximetry monitoring on brain injury (EEG, ultrasound), mortality
and other biomarkers
EEG: electroencephalogram
NIRS: near-infrared spectroscopy
ROP: retinopathy of prematurity
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D A T A A N D A N A L Y S E S
Comparison 1. Lower versus higher targeted oxygen saturations (no subgroups)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death or major disability by 18
to 24 months corrected age
(aligned definition)
5 4754 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.98, 1.10]
2 Death or major disability by 18
to 24 months corrected age
(trialist defined)
5 4751 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [1.00, 1.14]
3 Death to 18 to 24 months
corrected age
5 4873 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [1.03, 1.31]
4 Major disability by 18 to 24
months corrected age (aligned
definition)
5 3867 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.93, 1.09]
5 Major disability by 18 to 24
months corrected age (trialist
defined)
5 3864 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.94, 1.14]
6 Death to discharge 5 4958 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [1.03, 1.31]
7 Severe retinopathy of
prematurity or retinal therapy
(trialist defined)
5 4089 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.61, 0.85]
8 Patent ductus arteriosus
requiring medical or surgical
treatment
5 4928 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.95, 1.06]
9 Necrotising enterocolitis 5 4929 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [1.05, 1.47]
10 Cerebral palsy with GMFCS
level 2 or higher at 18 to 24
months corrected age
5 3877 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.79, 1.32]
11 Blindness 5 3875 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.65, 1.97]
12 Severe hearing loss 5 3869 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.73, 1.43]
13 Proportion of infants re-
admitted to hospital up to 18
to 24 months corrected age
1 295 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.93, 1.26]
14 Weight (grams) at discharge
home
1 295 Mean Difference (IV, Fixed, 95% CI) -52.0 [-214.25, 110.
25]
15 Weight (kilograms) at 18 or 24
months corrected age
1 280 Mean Difference (IV, Fixed, 95% CI) 0.80 [-0.24, 1.84]
16 Days of endotracheal
intubation
2 1386 Mean Difference (IV, Fixed, 95% CI) 0.28 [-1.16, 1.72]
17 Days of CPAP 3 2526 Mean Difference (IV, Fixed, 95% CI) -0.04 [-1.38, 1.30]
18 Days of supplemental oxygen 3 2507 Mean Difference (IV, Fixed, 95% CI) -8.78 [-12.02, -5.54]
19 Supplemental oxygen
requirement at 36 weeks
postmenstrual age
5 4175 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.81, 0.94]
20 Days on home oxygen 2 237 Mean Difference (IV, Fixed, 95% CI) -24.17 [-57.99, 9.
66]
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21 Quantitative Bayley III scores
(Composite Cognitive Score
(CCS))
2 1892 Mean Difference (IV, Fixed, 95% CI) 0.55 [-0.91, 2.00]
22 Quantitative Bayley III scores
(Composite Language Score
(CLS))
1 903 Mean Difference (IV, Fixed, 95% CI) 0.20 [-2.03, 2.43]
Comparison 2. Lower versus higher targeted oxygen saturations (primary outcome, subgrouped by gestational
age)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death or major disability by 18
to 24 months corrected age
(trialist defined)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 < 26 weeks 1 537 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.89, 1.32]
1.2 ≥ 26 weeks 1 697 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.86, 1.60]
Comparison 3. Lower versus higher targeted oxygen saturations (primary outcome, subgrouped by sex)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death or major disability by 18
to 24 months corrected age
(trialist defined)
1 941 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.97, 1.26]
1.1 Male 1 503 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.96, 1.33]
1.2 Female 1 438 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.87, 1.31]
Comparison 4. Lower versus higher targeted oxygen saturations (primary outcome, subgrouped by multiples)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death or major disability by 18
to 24 months corrected age
(trialist defined)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Singleton 1 670 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.94, 1.29]
1.2 Multiple 1 271 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.88, 1.39]
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Comparison 5. Lower versus higher targeted oxygen saturations (primary outcome, subgrouped by oximeter
calibration software)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death or major disability by 18
to 24 months corrected age
(aligned definition)
5 4684 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.98, 1.10]
1.1 Original algorithm 5 3003 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.94, 1.07]
1.2 Revised algorithm 3 1681 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [1.02, 1.24]
2 Death or major disability by 18
to 24 months corrected age
(trialist defined)
5 4681 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [1.00, 1.15]
2.1 Original algorithm 5 3000 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.95, 1.13]
2.2 Revised algorithm 3 1681 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [1.02, 1.24]
Comparison 6. Lower versus higher targeted oxygen saturations (secondary outcomes, subgrouped by oximeter
calibration software)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death by 18 to 24 months
corrected age
5 4803 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [1.03, 1.30]
1.1 Original 5 3087 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.91, 1.22]
1.2 Revised 3 1716 Risk Ratio (M-H, Fixed, 95% CI) 1.38 [1.13, 1.68]
2 Major disability by 18 to 24
months corrected age (aligned
definition)
5 3967 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.93, 1.09]
2.1 Original 5 2529 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.90, 1.09]
2.2 Revised 3 1438 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.91, 1.22]
3 Major disability by 18 to 24
months corrected age (trialist
defined)
5 3964 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.94, 1.14]
3.1 Original 5 2526 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.89, 1.17]
3.2 Revised 3 1438 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.91, 1.22]
4 Death to discharge 4 3757 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [1.03, 1.36]
4.1 Original 4 2575 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.90, 1.26]
4.2 Revised 2 1182 Risk Ratio (M-H, Fixed, 95% CI) 1.45 [1.15, 1.84]
5 Severe retinopathy of
prematurity or retinal therapy
4 3073 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.58, 0.84]
5.1 Original 4 2085 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.53, 0.84]
5.2 Revised 2 988 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.56, 1.05]
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Comparison 7. Lower versus higher targeted oxygen saturations (secondary outcomes, subgrouped by gestational
age)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death by 18 to 24 months
corrected age
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 < 26 weeks 1 550 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.95, 1.57]
1.2 ≥ 26 weeks 1 731 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.84, 1.86]
2 Major disability by 18 to 24
months corrected age (trialist
defined)
1 976 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.64, 1.35]
2.1 < 26 weeks 1 367 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.52, 1.37]
2.2 ≥ 26 weeks 1 609 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.59, 1.93]
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The title of the review was changed to the “Effects of targeting lower versus higher arterial oxygen saturations...” from the original
“...higher versus lower ...” to better reflect that, for the purposes of this review, lower oxygen targeting was considered the experimental
treatment.
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